Evidence map›Paper›PMID 34479754›Full record

ArticleEuropean urology2021

Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy.

Ruth Etzioni, Michael C Haffner, Roman Gulati

Abstract readEditorialComment
In one paragraph

Article in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ruth EtzioniDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA. Electronic address: retzioni@fredhutch.org.
Michael C HaffnerDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Pathology, University of Washington, Seattle, WA, USA.
Roman GulatiDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Modeling Precision Interventions for Prostate Cancer ControlU01CA253915 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D, TSODIKOV, ALEXANDER · 2020 to 2025
$6.5M
Statistical modeling to support population and translational cancer researchR50CA221836 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Roman Gulati · 2017 to 2026
$2.0M
NCI NIH HHS P50 CA097186NCI NIH HHS R50 CA221836NCI NIH HHS U01 CA253915
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Magnetic Resonance ImagingProstateBiopsyHumansMale

Identifiers

PMID34479754
PMCPMC11392599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.